NASDAQ$HALO
Halozyme Therapeutics Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Halozyme reported first quarter 2020 results, highlighting FDA approval for DARZALEX FASPROTM and a positive CHMP opinion.
Halozyme Therapeutics, Inc. reported a decrease in revenue for the first quarter of 2020, primarily due to a $30 million upfront payment from argenx in the prior year period. The company experienced a net loss of $6.1 million, or $0.04 per share, compared to a net income of $1.8 million, or $0.01 per share, in the first quarter of 2019. Despite these challenges, Halozyme reaffirmed its 2020 financial guidance, expecting revenues between $230 million and $245 million and earnings per share between $0.60 and $0.75.
- Received U.S. FDA approval for DARZALEX FASPROTM with a subcutaneous administration time of 3-5 minutes.
- Obtained a positive CHMP opinion recommending approval of DARZALEX® SC formulation in multiple current IV DARZALEX® indications.
- BLA accepted for subcutaneous fixed-dose combination of Perjeta® and Herceptin® utilizing ENHANZE® with FDA action date of October 18, 2020.
- Maintained 2020 financial guidance of $230 to $245 million in revenues and $0.60 to $0.75 earnings per share.
Headline financials
Revenue & EPS history
Halozyme · Revenue · Quarterly
$25.4M
Revenue by segment
Halozyme · $17.2M total across 2 segments · Q1 2020
- Royalties$16.8M-6.3%97.8%
- Revenues under collaborative agreements$385K-98.7%2.2%
Forward guidance
The Company's 2020 financial guidance remains unchanged from that first provided on January 14, 2020. For 2020 Halozyme continues to expect Revenues of $230 million to $245 million, representing growth of 17% to 25%; Earnings per share on a GAAP basis of $0.60 to $0.75 with the first quarter of sustainable profitability beginning in Q2 2020.
Tailwinds
- Revenues of $230 million to $245 million, representing growth of 17% to 25%
- Earnings per share on a GAAP basis of $0.60 to $0.75
- First quarter of sustainable profitability beginning in Q2 2020
- Continued monitoring of the impact of the COVID-19 pandemic on its business
- Updates from partners and suppliers on how their businesses are affected
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2020
+1.8%
Avg return
Earnings day
+4.4%
Avg return
5 days after
+1.8%
Avg return
30 days after
62%
32 / 52 earnings
Positive
+18.2%
Q1 2025
Best reaction
-12.8%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.7% | +1.1% | +6.5% | |
| Q4 2025 | -9.0% | -12.2% | -21.2% | |
| Q3 2025 | +2.7% | +3.1% | -4.9% | |
| Q1 2025 | +18.2% | +12.1% | -8.6% | |
| Q3 2024 | +13.0% | +16.1% | -4.7% | |
| Q2 2024 | +3.9% | +5.9% | +17.2% | |
| Q1 2024 | +2.8% | +5.6% | +25.9% | |
| Q4 2023 | +6.3% | +12.4% | +11.4% | |
| Q3 2023 | +9.1% | +4.7% | +12.3% | |
| Q2 2023 | +1.5% | +4.1% | -6.8% | |
| Q1 2023 | +13.9% | +8.9% | +12.8% | |
| Q4 2022 | +0.1% | -1.0% | -32.7% | |
| Q3 2022 | +7.4% | +16.6% | +25.0% | |
| Q2 2022 | -2.1% | -4.2% | -11.9% | |
| Q1 2022 | +3.3% | +8.2% | +20.4% | |
| Q4 2021 | +3.1% | +8.6% | +18.3% | |
| Q3 2021 | +2.6% | +4.3% | -15.0% | |
| Q2 2021 | +1.8% | +2.4% | +3.8% | |
| Q1 2021 | -10.3% | -9.5% | -17.2% | |
| Q4 2020 | +5.7% | -7.1% | -15.2% | |
| Q3 2020 | +12.9% | +34.6% | +45.2% | |
| Q2 2020 | -2.7% | -3.7% | -3.2% | |
| Q1 2020 | +0.2% | +2.7% | -1.4% | |
| Q4 2019 | -4.7% | -10.4% | -22.4% | |
| Q3 2019 | +6.4% | +13.9% | +12.8% | |
| Q2 2019 | -0.9% | -5.1% | -5.3% | |
| Q1 2019 | -3.1% | -5.9% | -10.9% | |
| Q4 2018 | -0.4% | +1.8% | -8.2% | |
| Q3 2018 | +0.7% | +0.6% | -1.6% | |
| Q2 2018 | +0.3% | -2.6% | +2.5% | |
| Q1 2018 | -7.3% | -3.0% | -7.2% | |
| Q4 2017 | +3.8% | +7.2% | +9.9% | |
| Q3 2017 | +12.2% | +6.9% | +11.5% | |
| Q2 2017 | -4.0% | -9.7% | -0.7% | |
| Q1 2017 | -1.6% | +3.1% | -7.3% | |
| Q4 2016 | +0.2% | +5.6% | +1.2% | |
| Q3 2016 | +14.2% | +48.7% | +33.7% | |
| Q2 2016 | -0.4% | +1.6% | +6.2% | |
| Q1 2016 | +3.7% | — | — | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | -12.8% | — | — | |
| Q2 2015 | -1.4% | — | — | |
| Q1 2015 | +2.8% | — | — | |
| Q4 2014 | +1.1% | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q2 2014 | +1.7% | — | — | |
| Q3 2010 | -1.4% | — | — | |
| Q3 2011 | -1.4% | — | — | |
| Q2 2010 | -3.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q1 2011 | +5.2% | — | — | |
| Q1 2010 | -2.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro